Breast Cancer Subtypes And Prognosis: Answers To Subgroup Classification Questions, Identifying The Worst Subgroup In Our Single-Center Series

preprint OA: closed
View at publisher

Abstract

PURPOSE: Because of advances in treatment, long life is now possible even in patients with metastatic BC. In many studies, the triple-negative breast cancer (TNBC) subgroup is stated to have the worst prognosis, as such patients are deprived of antihormonal and Herceptin therapy. While HER2 overexpression was interpreted as a poor prognostic factor before Herceptin, it was reported to be the worst prognostic subgroup of TNBC. In this study, we aimed to find the worst prognostic subgroup. METHODS: We reviewed the records of patients with BC who were admitted to our department between July 1999 and December 2019. We grouped the patients into four main groups (Luminal A, Luminal B, triple-negative, and HER2-enriched) and we recorded patient and treatment characteristics and oncological results. Survival curves were generated using the Kaplan–Meier method, and the significance of survival differences among the selected variables was compared by using the log-rank test. RESULTS: A total of 2474 patients with BC and after exclusions, statistical analysis was performed on 2017 patients with BC. The HER2 positivity rate was 23.7% and the TNBC patient rate was 11.7% (n = 236). The distribution of the four main groups was 47.1% for Luminal A, 34.1% for Luminal B, 7.1% for HER2-enriched, and 11.7% for the TN subgroup. Age (<35 years), no axillary surgery, Ki67≥15, high tumor grade, high mitotic index, the presence of skin infiltration, advanced T/N stage, the presence of metastasis, nontreatment with chemotherapy, less than 5 years of using TMX or AI, and being in the HER2-enriched subgroup were determined to be negative factors for overall survival as a result of multivariate analysis. CONCLUSIONS: The HER2-enriched subgroup had the worst prognosis despite receiving targeted therapy. However, treatment with trastuzumab increased survival 1.5-fold over that of the HER2-enriched subgroup that did not receive it.

My notes (saved in your browser only)

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-05-19T01:45:01.086888+00:00